Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Mass Drug Administration (MDA) and Mass Screening and Selective Treatment (MST) might be
applied as strategies for eliminating malaria when focusing on transmission stages. Many
studies either with MDA or MST has been done in low transmission areas demonstrated the
impact of those activities to reduce malaria transmission. However, in high transmission such
study is still very limited which is becoming the reason behind this study.
A randomized cluster trial of MST study using dihydroartemisinin-piperaquine plus primaquine
(DHP + PQ) will be conducted in some villages at the Belu regency, Nusa Tenggara TImur
province, Central Indonesia. There will be three arms in the study, i.e. (1) intervention arm
of mass screening and treatment with interval of 6 weeks; (2) intervention arm of mass
screening and treatment with interval of 3 months and (3) control arm without mass screening
and treatment. The intervention arm with 6 weeks interval represents a new proposed method to
detection malaria infections, while the intervention arm with 3 month interval represents the
Ministry of Health current policy of active case detection in Indonesia, and the third arm
will serve as the control for Ministry of Health's policy.
The study will be conducted in 6 months period and evaluate various parameters including
malaria incidence and proportion of anemia in monthly cohort school children (in arm1, 2 and
3), in addition to malaria prevalence in the community (only in arm 1 and arm 2). All
positive subject in all arms will receive supervised treatment. Secondary objectives are the
proportion of gametocytemia in the community, the proportion of malaria antibody of various
age groups, population genetic of local parasite, submicroscopic incidence based polymerase
chain reaction and the proportion of infective mosquitoes. Data analysis will be performed
according to the method for cluster randomized trial evaluation.
Phase:
Phase 4
Details
Lead Sponsor:
Indonesia University
Collaborator:
Walter and Eliza Hall Institute of Medical Research